Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03749187 · ClinicalTrials.gov registry record · Phase 1

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

A Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by University of California, San Francisco.

Active
Registry status
Phase 1
Development phase
78
Enrollment target
11
Study locations

NCT03749187: Active Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by University of California, San Francisco.

NCT03749187 is a Phase 1 study of Glioblastoma and Recurrent Glioblastoma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 78 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (28% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03749187, a Phase 1 study of Glioblastoma and Recurrent Glioblastoma, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
11
Study locations

Study Summary

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

Primary Outcome

Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.

Conditions Studied

Glioblastoma Recurrent Glioblastoma Malignant Glioma Low Grade Glioma WHO Grade III Glioma Recurrent WHO Grade III Glioma WHO Grade II Glioma IDH2 Gene Mutation Recurrent WHO Grade II Glioma IDH1 Gene Mutation

Interventions

  • DRUG Temozolomide (TMZ)
  • DRUG PARP Inhibitor BGB-290

Study Locations (11)

California

  • Children's Hospital Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Connecticut

  • Yale University - New Haven

Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New Jersey

  • Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center - Hackensack

North Carolina

  • Duke University Medical Center - Durham

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2019-04-03
Est. Completion 2029-07-30
Phase Phase 1
University of California, San Francisco

1,713 total trials

What the registry record for NCT03749187 still lists

NCT03749187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (28% lower).

The record links to 10 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide (TMZ) is the first listed.

NCT03749187 lists 11 locations in 10 states (California, Connecticut, Maryland).

Frequently Asked Questions

What is clinical trial NCT03749187 about?

NCT03749187 is a clinical study titled "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas". This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell gro...

What is the current status of trial NCT03749187?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2019-04-03. Estimated completion is 2029-07-30.

What conditions does trial NCT03749187 study?

This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Malignant Glioma, Low Grade Glioma, WHO Grade III Glioma.

What interventions are being tested in trial NCT03749187?

The interventions under investigation include: Temozolomide (TMZ) (DRUG), PARP Inhibitor BGB-290 (DRUG).

Who is sponsoring clinical trial NCT03749187?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03749187 being conducted?

This trial has 11 study locations across California, Connecticut, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03749187's enrollment target sits among peer trials

78 59th of 199 higher than 139 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02397668 · 78 participants · NA

    CorMatrix Cor TRICUSPID ECM Valve Replacement Study

  • NCT03321656 · 78 participants · Phase 2

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

  • NCT03687814 · 78 participants · NA

    Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

  • NCT04018872 · 78 participants · Phase 2

    Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03749187, the US trial registry maintained by the National Library of Medicine. NCT03749187 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.